1. FRI0196 NNC0109-0012 (anti-IL-20 MAB), well tolerated in healthy subjects and patients with rheumatoid arthritis. (23rd January 2014) Authors: Al Kotbi, N.; Jensen, L.; Graff, L.B. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 379 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. FRI0197 NNC0109-0012 (anti-IL-20 MAB), well tolerated in patients with rheumatoid arthritis. (23rd January 2014) Authors: Leszczyński, P.; Eshof, M.K.; Stegmann, H.V.B.; Hundahl Møller, N.P.; Graff, L.B. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 379 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME). (14th November 2014) Authors: Chalmers, J.R.; Schmitt, J.; Apfelbacher, C.; Dohil, M.; Eichenfield, L.F.; Simpson, E.L.; Singh, J.; Spuls, P.; Thomas, K.S.; Admani, S.; Aoki, V.; Ardeleanu, M.; Barbarot, S.; Berger, T.; Bergman, J.N.; Block, J.; Borok, N.; Burton, T.; Chamlin, S.L.; Deckert, S. Journal: British journal of dermatology Issue: Volume 171:Number 6(2014:Dec.) Page Start: 1318 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME). (1st December 2014) Authors: Chalmers, J.R.; Schmitt, J.; Apfelbacher, C.; Dohil, M.; Eichenfield, L.F.; Simpson, E.L.; Singh, J.; Spuls, P.; Thomas, K.S.; Admani, S.; Aoki, V.; Ardeleanu, M.; Barbarot, S.; Berger, T.; Bergman, J.N.; Block, J.; Borok, N.; Burton, T.; Chamlin, S.L.; Deckert, S. Journal: British journal of dermatology Issue: Volume 171:Number 6(2014:Dec.) Page Start: 1318 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗